Abstract submissions are peer-reviewed for quality research, scientific content, and logical presentation. Accepted abstracts will be scheduled as either a poster or an oral presentation.

Guidelines for Submission

Individuals submitting abstracts agree that if their abstract is accepted, they will attend the meeting and present their abstract as scheduled. The presenting author should be able to answer substantive questions about all aspects of their study.

Once an abstract has been accepted and scheduled, it cannot be withdrawn. Authors agree to have the abstract published in the Conference Abstract Book and as a supplement to the journal Antiviral Therapy. Abstracts must be submitted via the on-line submission system on this web site. The Abstract Body must be submitted as either a Microsoft Word (.doc) or Rich Text Format (.rtf) document (do not send e-mail attachments).

Help for submitting abstracts electronically appears on the web site. Submitters will be prompted through the electronic submission process.

Please carefully review the abstract prior to its submission. Note that if an abstract has been entered but the final submission button has not been clicked, it is not technically submitted and therefore will not be reviewed. Edits to the abstract (other than designating a different category) may be made online after submission up until the deadline of 17:00 h PDT, March 31st, 2007. Do not make multiple submissions of the same abstract with incremental changes over the Internet. Editing a submitted abstract requires use of the confirmation number that you will receive by email after you have completed the submission process (see Notification and Correspondence, below).

Abstract Selection Process

Abstract submissions will be peer reviewed by the Conference Organizers and a panel of ad hoc reviewers. To minimize subjectivity in the scoring process, any reviewer with a conflict of interest (as defined by NIH rules, e.g., co-authorship, financial interest, or scientific/personal conflict with the authors that could affect objectivity of scoring) will be excluded from scoring or discussing the abstract in question. In the final rankings, mean score and standard deviation will be calculated, and the reviewers' scores will be anonymous. Abstract acceptance is based upon abstract quality, the potential significance of the observations, and the rigor with which the scientific methods were applied. Further, the Conference Organizers consider thematic balance in determining which abstracts will be presented orally.

Notification and Correspondence

Authors submitting abstracts will receive email confirmation of their submission. Please print and retain your confirmation number as this number will be needed to re-enter the submission site. Abstract dispositions will be e-mailed to corresponding authors by May 18, 2007. Abstract dispositions will not be provided by telephone.

Late Breaker Abstracts

Abstracts that contain new data not available at the original abstract deadline may be submitted for consideration for presentation during oral abstract sessions during the Conference. Only abstracts containing novel, cutting-edge information will be considered. Because of the limited number of Conference time slots and the nature of late breakers, very few submissions will be accepted for presentation. Late Breaker abstracts must be submitted via the Internet. Late Breaker online submission will open June 4, 2007. The deadline for late breaker abstract submission is 1700 PDT on July 9th, 2007.

Published Abstracts

Accepted abstracts will be published in the Program and Abstracts of AIDS Vaccine 2007 and distributed to registrants. Abstracts will also be published as a supplement to Antiviral Therapy.

Copyright and Webcast Policy

By submitting an abstract, authors and co-authors transfer any copyrights and grant permission to AIDS Vaccine 2007 to audio/video record oral presentations.

Click here for abstract directions and submission form